Hormone Therapy Labeling Should Include "Black Box" Warning On Dementia Risk, FDA Says

FDA requests labeling warning on increased dementia risk with use of estrogen and combination estrogen/progestin products. The updated labeling template incorporates findings from Women’s Health Initiative Memory Study.